STOCK TITAN

Sight Sciences (SGHT) CFO sells 2,616 shares to cover tax liability

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Sight Sciences, Inc. Chief Financial Officer James Rodberg reported a small sale of company stock on January 16, 2026. He sold 2,616 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability arising from the vesting of restricted stock units. The shares were sold in multiple trades at prices ranging from $6.44 to $6.69.

After this transaction, Rodberg beneficially owned 151,230 shares, consisting of 39,451 shares of common stock and 111,779 shares that will be received upon future vesting and settlement of restricted stock units.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rodberg James

(Last) (First) (Middle)
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/16/2026 S 2,616(1) D $6.62(2) 151,230(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
2. Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Includes (i) 39,451 shares of common stock, and (ii) 111,779 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested.
/s/Jeremy Hayden, Attorney-in-Fact for James Rodberg 01/21/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SGHT CFO James Rodberg report on this Form 4?

Chief Financial Officer James Rodberg reported selling 2,616 shares of Sight Sciences, Inc. common stock on January 16, 2026. The sale was to cover his tax liability related to the vesting of restricted stock units.

At what price did the SGHT CFO sell his Sight Sciences shares?

James Rodberg sold the 2,616 shares at a weighted average price of $6.62 per share. The trades occurred in multiple transactions at prices between $6.44 and $6.69 per share.

How many Sight Sciences (SGHT) shares does the CFO own after this transaction?

Following the sale, James Rodberg beneficially owned 151,230 shares of Sight Sciences. This includes 39,451 shares of common stock and 111,779 shares that will be acquired upon vesting and settlement of restricted stock units.

Why did the SGHT CFO sell 2,616 shares of Sight Sciences common stock?

The Form 4 states that the 2,616 shares were sold to cover tax liability arising from the vesting of restricted stock units, rather than as a discretionary open-market sale.

What role does James Rodberg hold at Sight Sciences (SGHT)?

James Rodberg is identified as an officer of Sight Sciences, Inc., serving as the company’s Chief Financial Officer.

Is this Sight Sciences Form 4 filed by more than one reporting person?

No. The filing indicates it is a Form filed by one reporting person, namely Chief Financial Officer James Rodberg.

Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Latest SEC Filings

SGHT Stock Data

339.44M
41.87M
20.66%
50.37%
1.99%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MENLO PARK